5 Most Shorted Mid-Cap and Small-Cap Stocks to Buy Now

In this article, we will list the 5 Most Shorted Mid-Cap and Small-Cap Stocks to Buy Now. Please visit 10 Most Shorted Mid-Cap and Small-Cap Stocks to Buy Now if you would like to see the extended list and the methodology behind it.

5. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Short Float: 39.19%

Market Cap: $1.92 Billion

Stock Upside Potential: 53.97%

Number of hedge fund holders: 35

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 13, H.C. Wainwright reiterated Intellia Therapeutics (NASDAQ:NTLA) as a Buy but lowered the price target to $25 from $30. The price target cut is in response  to a recent share offering expected to result in significant dilution.

The company announced a $180 million follow-on equity offering of 16.7 million shares at $10.75 a share. The price offering represents an 18.6%  discount to the stock’s closing price following the announcement. While the offering was planned at $150 million, it was upsized to $180 million to generate more gross proceeds.

Amid the price target cut due to dilution concerns, H.C. Wainwright remains bullish with a Buy rating, impressed by Intellia Therapeutics’ top-line results in the Phase 3 lonvo-z trials, with 62% of patients turning out attack-free and therapy-free with no adverse events. The company is planning a regulatory submission for a potential first-half 2027 US launch.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage biotechnology company focused on developing potentially curative treatments using CRISPR/Cas9 gene editing technology. The company aims to permanently modify disease-causing genes in the human body through a single course of treatment.